DEF: Matinas BioPharma Holdings Proposes Reverse Stock Split, Increases Authorized Shares, and New Equity Incentive Plan

Matinas BioPharma Holdings seeks stockholder approval for a reverse stock split, an increase in authorized shares, and a new equity incentive plan at its upcoming annual meeting.

Summary

• Matinas BioPharma Holdings, Inc. is holding its Annual Meeting of Stockholders on June 23, 2025, to vote on several key proposals.
• The proposals include the election of five directors, an advisory vote on executive compensation, and amendments to the Certificate of Incorporation.
• One proposed amendment involves a reverse stock split with a ratio ranging from 1-for-2 to 1-for-199, to be determined by the Board of Directors.
• Another amendment seeks to increase the number of authorized shares of common stock from 250,000,000 to 500,000,000.
• Stockholders will also vote on approving the Company's 2025 Equity Incentive Plan.
• The Board recommends voting FOR all proposals.

Sentiment

Score: 6

Explanation: The document is neutral in tone, presenting factual information about the upcoming shareholder vote. While the proposals have potential benefits, there are also risks involved, resulting in a moderate sentiment score.

Positives

• The proposed reverse stock split could enhance the appeal of the company's common stock to institutional investors and the general investing public.
• Increasing the number of authorized shares provides flexibility for future financings, investment opportunities, and acquisitions.
• The 2025 Equity Incentive Plan aims to attract, retain, and motivate key employees and service providers, potentially driving long-term value creation.

Negatives

• A reverse stock split may be viewed negatively by some investors, potentially leading to a decrease in market capitalization.
• The increased proportion of unissued authorized shares could be seen as having an anti-takeover effect.
• Issuance of additional shares could dilute the voting rights and earnings per share of existing stockholders.

Risks

• There is no guarantee that a reverse stock split will increase the market price of the common stock or maintain the desired results.
• The market price of the common stock is dependent on many factors, including business and financial performance, general market conditions, and prospects for future success.
• A reverse stock split may result in some stockholders owning odd lots of less than 100 shares, which may be more difficult to sell.
• The company may not be able to meet the continued listing standards of the NYSE MKT even with a reverse stock split.

Future Outlook

The company may explore additional financing opportunities or strategic transactions that would require the issuance of additional shares of common stock.

Management Comments

• Our Board believes that the election of the director nominees identified herein, the approval, on an advisory basis, of the executive compensation of the Company's named executive officers, the Reverse Stock Split Proposal, the Increase to Authorized Proposal and the proposal to approve the Matinas BioPharma Holdings 2025 Equity Incentive Plan are advisable and in the best interests of the Company and its stockholders and recommends that you vote FOR each of these proposals.

Industry Context

Biopharmaceutical companies often use equity incentive plans to attract and retain talent, and reverse stock splits are sometimes employed to maintain listing compliance or improve stock perception.

Comparison to Industry Standards

• Comparable companies such as Kintara Therapeutics, Inc. and Renovaro Inc. have had similar board members serving on their boards.
• Other companies like Zoomcar Holdings, Inc. and Backblaze, Inc. have directors serving on multiple boards, similar to Evelyn D'An.
• Companies like Organovo Holdings, Inc. and Cronus Pharma, LLC have executives with experience in both public and private companies, mirroring the experience of some of Matinas BioPharma's directors.

Management Changes

Related Party Transactions

• Affiliates of Highbridge Capital Management, LLC purchased 466,666 shares of common stock and warrants to purchase 466,666 shares of common stock, for $7.0 million.
• Sanitam Partners LLC, and its affiliates, Adam K Stern, HEZBAY Holdings LLC, Ari Kluger, Platinum Point Capital, LLC, Brian Freifeld, Pembroke & Partners LLC and Robert J. Eide purchased Preferred Stock convertible into an aggregate of 5,631,404 shares of common stock, and Warrants convertible into an aggregate of 11,262,808 shares of common stock, for an aggregate of 16,894,212 shares of common stock, on fully-diluted basis, subject to the Blocker, in the Offering for an aggregate of $3.3 million.

Stakeholder Impact

• Shareholders will be affected by the reverse stock split, the increase in authorized shares, and the equity incentive plan.
• Employees may be affected by the equity incentive plan, which aims to attract, retain, and motivate them.
• The company's financial stability and future prospects could be impacted by the decisions made at the Annual Meeting.

Next Steps

• Stockholders need to vote on the proposals before the Annual Meeting on June 23, 2025.
• The Board will determine whether to implement the reverse stock split and the specific ratio to be used.
• The Company may explore additional financing opportunities or strategic transactions.

Key Dates

Keywords

reverse stock split, authorized shares, equity incentive plan, annual meeting, proxy statement, executive compensation, directors, Matinas BioPharma, stockholders